cardiology careers collections past issues search home
     

J Am Coll Cardiol, 2008; 51:1098-1103, doi:10.1016/j.jacc.2007.12.010
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parolini, C.
Right arrow Articles by Chiesa, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Parolini, C.
Right arrow Articles by Chiesa, G.
Related Collections
Right arrowRelated Article

PRECLINICAL STUDY: APO: A-IMILANO

Dose-Related Effects of Repeated ETC-216 (Recombinant Apolipoprotein A-IMilano/1-Palmitoyl-2-Oleoyl Phosphatidylcholine Complexes) Administrations on Rabbit Lipid-Rich Soft Plaques

In Vivo Assessment by Intravascular Ultrasound and Magnetic Resonance Imaging

Cinzia Parolini, PhD*, Marta Marchesi, PhD*, Paolo Lorenzon*, Mauro Castano, PhD{dagger}, Elena Balconi, BS*, Luigi Miragoli{dagger}, Linda Chaabane, PhD{dagger}, Alberto Morisetti, BS{dagger}, Vito Lorusso, BS{dagger}, Bradley J. Martin, PhD{ddagger}, Charles L. Bisgaier, PhD{ddagger}, Brian Krause, PhD{ddagger}, Roger S. Newton, PhD{ddagger}, Cesare R. Sirtori, MD, PhD* and Giulia Chiesa, PhD*,*

* Department of Pharmacological Sciences, University of Milan, Milan, Italy
{dagger} Bracco Imaging SpA, Colleretto Giacosa, Turin, Italy
{ddagger} Esperion Therapeutics, Pfizer Inc., Plymouth, Michigan.

Manuscript received June 28, 2008; revised manuscript received November 8, 2008, accepted December 2, 2008.

* Reprint requests and correspondence: Dr. Giulia Chiesa, Department of Pharmacological Sciences, via Balzaretti, 9, 20133 Milan, Italy. (Email: giulia.chiesa{at}unimi.it).

Objectives: This study sought to evaluate in vivo the minimal dose of apolipoprotein (apo) A-IMilano phospholipid complex (recombinant apoA-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complexes [ETC-216]) able to induce atherosclerosis regression in a rabbit model of lipid-rich plaques.

Background: A single high dose of recombinant apoA-IMilano has promoted atherosclerosis regression in animal models. More recently, regression of atherosclerosis was achieved in coronary patients by repeated infusions of ETC-216.

Methods: Thirty-six rabbits underwent perivascular injury at both carotid arteries, followed by a 1.5% cholesterol diet. After 90 days, rabbits were randomly divided into 6 groups and treated 5 times with vehicle or ETC-216 at 5, 10, 20, 40, or 150 mg/kg dose every 4 days. Carotid plaque changes were evaluated in vivo by intravascular ultrasound (IVUS) and magnetic resonance imaging (MRI), performed before and at the end of treatments. Magnetic resonance imaging scans were also recorded after administration of the second dose for rabbits infused with vehicle 40 or 150 mg/kg.

Results: Atheroma volume in vehicle-treated rabbits increased dramatically between the first and the second IVUS analyses (+26.53%), whereas in ETC-216–treated animals, a reduced progression at the lower doses and a significant regression at the higher doses, up to –6.83%, was detected. Results obtained by MRI analysis correlated significantly with those at IVUS (r = 0.706; p < 0.0001). The MRI evaluations after the second infusion established that a significant regression was achieved with only 2 administrations of the highest dose.

Conclusions: These results confirm the efficacy of ETC-216 for atherosclerosis treatment and provide guidance for dose selection and frequency to obtain a significant reduction of plaque volume.

Abbreviations and Acronyms
  apo = apolipoprotein
  ETC-216 = recombinant apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complexes
  HDL = high-density lipoprotein
  IVUS = intravascular ultrasound
  MRI = magnetic resonance imaging


Related Article

ApoA-IMilano/Phospholipid Complex: Clinical Implications of Dose-Response Studies in Rabbit Atherosclerosis With Intravascular Ultrasound and Magnetic Resonance Imaging
Xue-Qiao Zhao and B. Greg Brown
J. Am. Coll. Cardiol. 2008 51: 1110-1111. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
X.-Q. Zhao and B. G. Brown
ApoA-I(Milano)/phospholipid complex: clinical implications of dose-response studies in rabbit atherosclerosis with intravascular ultrasound and magnetic resonance imaging.
J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1110 - 1111.
[Full Text] [PDF]



 
  cardiology careers collections past issues search home